Moderna, Inc. (MRNA)
MRNANASDAQ-GSBiotechnology: Biological Products (No Diagnostic Substances)
$253.50
+2.67 (+1.06%) today
At the close, Nov 10, 4:00 PM ET. Pre-market $253.50 +1.06%
- Market cap
- $102.74bn
- P/E
- –
- EPS, last 4 quarters
- $-4.88
- Dividend yield
- –
- Day range
- –
- 52-week range
- $22.28 to $280.80
- Average volume
- 16.13m
- Previous close
- $250.83
Analysts
20 coveringHold2 buy, 15 hold, 3 sell
Targets a year out average $145.38, -42.7% from here
Earnings
next estimate $-2.30Next report
Dec 2025
+18.9%
Mar 2026
+60.9%
Jun 2026
0.0%
Sep 2026
+134.6%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $678.00m | $389.00m | $145.00m | $1.31bn |
| Gross profit | $226.00m | -$566.00m | $52.00m | $995.00m |
| Operating income | -$857.00m | -$1.39bn | -$815.00m | $130.00m |
| Net income | -$826.00m | -$1.34bn | -$782.00m | $162.00m |
Last four quarters: revenue $2.52bn, margin -110.5%, free cash flow -$1.97bn
News
8 latest- Top Stock Picks for Week of November 9, 2026Zacks · 18 hours ago
- Noteworthy ETF Inflows: RSP, MRNA, PTC, CCLBNK Invest · 22 hours ago
- Moderna's Q3 Numbers May Have Seemed Impressive, but They Aren't Enough to Make the Stock a BuyThe Motley Fool · 1 day ago
- Stock Indexes Settle Mostly Higher as Chipmakers ReboundBarchart · 1 day ago
- Can Moderna's First Cancer Therapy Win FDA Approval in 2027?Zacks · 1 day ago
- Moderna Q3 Earnings Call Highlights Raised Outlook and OncologyZacks · 2 days ago
- BioNTech vs. Moderna: The COVID Vaccine Giants Are Entering a New Era. One Stock Could Have the Edge for 2027The Motley Fool · 2 days ago
- Zacks Investment Ideas feature highlights: Moderna, AbbVie, Eli Lilly and MerckZacks · 2 days ago
The company
Moderna is a pioneer and leader in the field of mRNA medicine. Through the advancement of its technology platform, Moderna is reimagining how medicines are made to transform how we treat and prevent diseases. Since its founding, Moderna's mRNA platform has enabled the development of vaccines and therapeutics across infectious diseases, cancer, rare diseases and more. With a global team and a unique culture, driven by the company's values and mindsets, Moderna's mission is to deliver the greatest possible impact to people through mRNA medicines.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- modernatx.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.